Sign In
Buy CLSN
$1.56
+0.0600 (+4.00%)
At Close: Jan 27, 2023
Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress
03:30pm, Thursday, 21'st Apr 2022 GlobeNewswire Inc.
Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows Neutralizing Activity Against 2 Strains of the COVID-19 Virus
Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress
11:30am, Thursday, 21'st Apr 2022
Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows Neutralizing Activity Against 2 Strains of the COVID-19 Virus
Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting
12:30pm, Thursday, 14'th Apr 2022 GlobeNewswire Inc.
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR Annual Meeting
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR A nnual M eeti ng
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022
02:01pm, Wednesday, 13'th Apr 2022 Benzinga
Upgrades
According to Oppenheimer, the prior rating for Apollo Global Management Inc (NYSE:APO) was changed from Perform to Outperform. In the fourth quarter, Apollo Global Management showed an EPS of
Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress
08:30am, Tuesday, 12'th Apr 2022
LAWRENCEVILLE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced it
Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
08:30pm, Friday, 08'th Apr 2022 GlobeNewswire Inc.
LAWRENCEVILLE, NJ, April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered dir
Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
04:30pm, Friday, 08'th Apr 2022
LAWRENCEVILLE, NJ, April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direc
Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial
12:30pm, Wednesday, 06'th Apr 2022 GlobeNewswire Inc.
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR Annual Meeting being held April 8-13 in New Orleans, LA
Why Celsion Shares Are Pulling Back Today
09:39am, Wednesday, 06'th Apr 2022
Celsion Corp (NASDAQ: CLSN) shares are trading lower Wednesday after the company announced a $7 million registered direct offering priced at-the-market under Nasdaq rules. What To Know: The offering
Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial
08:30am, Wednesday, 06'th Apr 2022
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR A nnual M eeti ng being held April 8-13 in New Orleans, LA
Why Celsion Stock Is Surging Today
06:50pm, Tuesday, 05'th Apr 2022 Benzinga
Celsion Corp (NASDAQ: CLSN) shares are trading higher Tuesday as traders circulate a Zacks Small-Cap Research note with a $37 valuation target on the stock.
Zacks analyst David Bautz highlighted the
Why Celsion Stock Is Surging Today
03:17pm, Tuesday, 05'th Apr 2022
Celsion Corp (NASDAQ: CLSN) shares are trading higher Tuesday as traders circulate a Zacks Small-Cap Research note with a $37 valuation target on the stock. Zacks analyst David Bautz highlighted the
Celsion Corporation's (CLSN) CEO Michael Tardugno on Q4 2021 Results - Earnings Call Transcript
01:41pm, Thursday, 31'st Mar 2022
Celsion Corporation's (CLSN) CEO Michael Tardugno on Q4 2021 Results - Earnings Call Transcript
Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022
09:00am, Thursday, 24'th Mar 2022
LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, anno
